Verastem's Shares Not Fully Valuing its Growth Potential, RBC Says

MT Newswires Live

Yesterday

Verastem's (VSTM) shares are not fully valuing its growth potential, considering a "major upcoming catalyst" and the A+F commercial franchise on track for profitability by year-end, RBC Capital Markets analysts said in a Friday note.

Analysts said that the company's 7375 mechanism has the potential to enable a better clinical profile, with potential across lines of therapy.

RBC said that the company's new launch strategy focusing on driving depth, earlier prescribing, and refills and durability appears to be working well.

Analysts said that Verastem shares do not fully reflect the value of the recent approval for Av-Fak in low-grade serous ovarian cancer.

RBC has an outperform speculative risk rating on the stock and a $14 price target.

Price: 7.65, Change: +0.10, Percent Change: +1.32

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2668092484"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2668092484\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2668092484?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-18 22:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2668092484","market":"hk","top_or_hot":-1,"title":"Verastem's Shares Not Fully Valuing its Growth Potential, RBC Says","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/VSTM\">Verastem</a>'s (VSTM) shares are not fully valuing its growth potential, considering a \"major upcoming catalyst\" and the A+F commercial franchise on track for profitability by year-end, RBC Capital Markets analysts said in a Friday note.</p><p>Analysts said that the company's 7375 mechanism has the potential to enable a better clinical profile, with potential across lines of therapy.</p><p>RBC said that the company's new launch strategy focusing on driving depth, earlier prescribing, and refills and durability appears to be working well.</p><p>Analysts said that Verastem shares do not fully reflect the value of the recent approval for Av-Fak in low-grade serous ovarian cancer.</p><p>RBC has an outperform speculative risk rating on the stock and a $14 price target.</p><p>Price: 7.65, Change: +0.10, Percent Change: +1.32</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Verastem's Shares Not Fully Valuing its Growth Potential, RBC Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVerastem's Shares Not Fully Valuing its Growth Potential, RBC Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-09-18 22:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/VSTM\">Verastem</a>'s (VSTM) shares are not fully valuing its growth potential, considering a \"major upcoming catalyst\" and the A+F commercial franchise on track for profitability by year-end, RBC Capital Markets analysts said in a Friday note.</p><p>Analysts said that the company's 7375 mechanism has the potential to enable a better clinical profile, with potential across lines of therapy.</p><p>RBC said that the company's new launch strategy focusing on driving depth, earlier prescribing, and refills and durability appears to be working well.</p><p>Analysts said that Verastem shares do not fully reflect the value of the recent approval for Av-Fak in low-grade serous ovarian cancer.</p><p>RBC has an outperform speculative risk rating on the stock and a $14 price target.</p><p>Price: 7.65, Change: +0.10, Percent Change: +1.32</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2668092484","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2668092484","pubTimestamp":1789743079,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Verastem's  shares are not fully valuing its growth potential, considering a \"major upcoming catalyst\" and the A+F commercial franchise on track for profitability by year-end, RBC Capital Markets analysts said in a Friday note.Analysts said that the company's 7375 mechanism has the potential to enable a better clinical profile, with potential across lines of therapy.RBC said that the company's new launch strategy focusing on driving depth, earlier prescribing, and refills and durability appears to be working well.Analysts said that Verastem shares do not fully reflect the value of the recent approval for Av-Fak in low-grade serous ovarian cancer.RBC has an outperform speculative risk rating on the stock and a $14 price target.Price: 7.65, Change: +0.10, Percent Change: +1.32","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","VSTM":"Verastem"},"translate_title":"加拿大皇家银行表示，Verastem 的股票并未充分发挥其增长潜力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VSTM":1.5},"content_text":"Verastem's (VSTM) shares are not fully valuing its growth potential, considering a \"major upcoming catalyst\" and the A+F commercial franchise on track for profitability by year-end, RBC Capital Markets analysts said in a Friday note.Analysts said that the company's 7375 mechanism has the potential to enable a better clinical profile, with potential across lines of therapy.RBC said that the company's new launch strategy focusing on driving depth, earlier prescribing, and refills and durability appears to be working well.Analysts said that Verastem shares do not fully reflect the value of the recent approval for Av-Fak in low-grade serous ovarian cancer.RBC has an outperform speculative risk rating on the stock and a $14 price target.Price: 7.65, Change: +0.10, Percent Change: +1.32","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}